Midregional pro atrial natriuretic peptide: a novel important biomarker for noise annoyance-induced cardiovascular morbidity and mortality?
Atrial Natriuretic Factor
/ blood
Biomarkers
/ blood
Cardiovascular Diseases
/ blood
Cause of Death
/ trends
Cross-Sectional Studies
Disease Progression
Female
Follow-Up Studies
Germany
/ epidemiology
Humans
Male
Middle Aged
Morbidity
/ trends
Prospective Studies
Registries
Risk Factors
Survival Rate
/ trends
Time Factors
Cardiovascular disease
Midregional pro atrial natriuretic peptide
Mortality
Noise annoyance
Risk factor
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
11
02
2020
accepted:
06
04
2020
pubmed:
20
4
2020
medline:
18
8
2021
entrez:
20
4
2020
Statut:
ppublish
Résumé
Environmental noise exposure has been associated with increased cardiovascular morbidity and mortality. Recently, noise annoyance was shown to induce atrial fibrillation, which was accompanied by significantly increased levels of midregional pro atrial natriuretic peptide (MR-proANP). Therefore, the aim of the present study was to analyze the association between noise annoyance, MR-proANP, incident cardiovascular events, and all-cause mortality. Levels of MR-proANP were measured in the first 5000 participants of the population-based Gutenberg Health Study. Annoyance was assessed separately for aircraft, road traffic, railway, neighborhood, and industrial/construction noise during the day and sleep. In cross-sectional analyses, aircraft noise annoyance during day and sleep, industrial/construction noise annoyance during day, and railway noise annoyance during sleep were independently associated with increased levels of MR-proANP after multivariable adjustment. After a 5-year follow-up period, there were 43 cases of incident atrial fibrillation and 103 of incident cardiovascular disease (comprising atrial fibrillation, coronary artery disease, myocardial infarction, heart failure, or stroke). Moreover, there were 301 deaths after a mean follow-up of 7.42 ± 1.66 years. An odds ratio (OR) of 2.82 ([95% confidence interval (CI) 1.86; 4.35], p < 0.0001) for incident atrial fibrillation and an OR of 1.49 ([95% CI 1.13; 1.96], p = 0.0046) for incident cardiovascular disease per 1-standard deviation (SD) increase in MR-proANP levels were found. A 36% (hazard ratio: 1.36 [95% CI 1.19; 1.55], p < 0.0001) higher risk of death was found per 1-SD increase in MR-proANP levels. Noise annoyance may contribute to cardiovascular morbidity and mortality and is characterized by increased levels of MR-proANP.
Sections du résumé
BACKGROUND
BACKGROUND
Environmental noise exposure has been associated with increased cardiovascular morbidity and mortality. Recently, noise annoyance was shown to induce atrial fibrillation, which was accompanied by significantly increased levels of midregional pro atrial natriuretic peptide (MR-proANP). Therefore, the aim of the present study was to analyze the association between noise annoyance, MR-proANP, incident cardiovascular events, and all-cause mortality.
METHODS
METHODS
Levels of MR-proANP were measured in the first 5000 participants of the population-based Gutenberg Health Study. Annoyance was assessed separately for aircraft, road traffic, railway, neighborhood, and industrial/construction noise during the day and sleep.
RESULTS
RESULTS
In cross-sectional analyses, aircraft noise annoyance during day and sleep, industrial/construction noise annoyance during day, and railway noise annoyance during sleep were independently associated with increased levels of MR-proANP after multivariable adjustment. After a 5-year follow-up period, there were 43 cases of incident atrial fibrillation and 103 of incident cardiovascular disease (comprising atrial fibrillation, coronary artery disease, myocardial infarction, heart failure, or stroke). Moreover, there were 301 deaths after a mean follow-up of 7.42 ± 1.66 years. An odds ratio (OR) of 2.82 ([95% confidence interval (CI) 1.86; 4.35], p < 0.0001) for incident atrial fibrillation and an OR of 1.49 ([95% CI 1.13; 1.96], p = 0.0046) for incident cardiovascular disease per 1-standard deviation (SD) increase in MR-proANP levels were found. A 36% (hazard ratio: 1.36 [95% CI 1.19; 1.55], p < 0.0001) higher risk of death was found per 1-SD increase in MR-proANP levels.
CONCLUSIONS
CONCLUSIONS
Noise annoyance may contribute to cardiovascular morbidity and mortality and is characterized by increased levels of MR-proANP.
Identifiants
pubmed: 32306084
doi: 10.1007/s00392-020-01645-6
pii: 10.1007/s00392-020-01645-6
pmc: PMC7806548
doi:
Substances chimiques
Biomarkers
0
Atrial Natriuretic Factor
85637-73-6
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-39Subventions
Organisme : BMBF
ID : BMBF 01EO1503
Références
Int J Cardiol. 2018 Aug 1;264:79-84
pubmed: 29695315
Am J Hypertens. 2009 Apr;22(4):425-31
pubmed: 19214167
J Am Coll Cardiol. 2018 Feb 13;71(6):688-697
pubmed: 29420965
Noise Health. 2003 Jan-Mar;5(18):1-11
pubmed: 12631430
Int J Environ Res Public Health. 2018 Mar 14;15(3):
pubmed: 29538344
Eur Heart J. 2017 Feb 21;38(8):557-564
pubmed: 27460891
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Jun;55(6-7):824-9
pubmed: 22736163
Eur J Prev Cardiol. 2015 Jun;22(6):693-700
pubmed: 24906365
Clin Res Cardiol. 2015 Jul;104(7):574-81
pubmed: 25665711
Clin Res Cardiol. 2015 Jan;104(1):23-30
pubmed: 25145323
Eur Heart J. 2016 Aug 1;37(29):2315-2381
pubmed: 27222591
J Int Med Res. 2018 Aug;46(8):3017-3029
pubmed: 30027789
Clin Res Cardiol. 2019 Dec;108(12):1313-1323
pubmed: 30953178
Biofactors. 2019 Jul;45(4):495-506
pubmed: 30937979
Clin Res Cardiol. 2020 Aug;109(8):957-966
pubmed: 32002634
Hypertension. 2012 Aug;60(2):288-95
pubmed: 22689741
PLoS One. 2016 May 19;11(5):e0155357
pubmed: 27195894
Basic Res Cardiol. 2019 Oct 29;114(6):46
pubmed: 31664594
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jan;56(1):131-43
pubmed: 23275948
Eur Heart J. 2020 Feb 1;41(6):772-782
pubmed: 31769799
Environ Health Perspect. 2017 Sep 07;125(9):097004
pubmed: 28934719
Dtsch Arztebl Int. 2019 Apr 5;116(14):245-250
pubmed: 31092312
Eur Heart J. 2020 Feb 1;41(6):783-785
pubmed: 31859340
Noise Health. 2002;4(16):1-11
pubmed: 12537836
Eur Heart J. 2013 Dec;34(45):3508-14a
pubmed: 23821397
Oxid Med Cell Longev. 2019 Nov 11;2019:4623109
pubmed: 31814877
Eur Heart J. 2010 Dec;31(24):3024-31
pubmed: 20852293
Circulation. 2006 Feb 21;113(7):938-45
pubmed: 16476848
Clin Res Cardiol. 2018 Jun;107(6):471-478
pubmed: 29383439
Int J Environ Res Public Health. 2015 Oct 14;12(10):12735-60
pubmed: 26473905
Int J Environ Res Public Health. 2018 Feb 22;15(2):
pubmed: 29470452
Clin Res Cardiol. 2019 Apr;108(4):438-447
pubmed: 30244327
Eur Heart J. 2017 Oct 1;38(37):2838-2849
pubmed: 28329261
Biomark Med. 2019 Dec;13(17):1493-1507
pubmed: 31659915
Eur Heart J. 2014 Apr;35(13):829-36
pubmed: 24616334
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Eur Heart J. 2017 Feb 21;38(8):550-556
pubmed: 27460892
Eur Heart J. 2018 Oct 7;39(38):3528-3539
pubmed: 29905797
Br J Pharmacol. 2017 Jun;174(12):1591-1619
pubmed: 27187006